These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31051099)

  • 1. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.
    Maji B; Gangopadhyay SA; Lee M; Shi M; Wu P; Heler R; Mok B; Lim D; Siriwardena SU; Paul B; Dančík V; Vetere A; Mesleh MF; Marraffini LA; Liu DR; Clemons PA; Wagner BK; Choudhary A
    Cell; 2019 May; 177(4):1067-1079.e19. PubMed ID: 31051099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into a high fidelity variant of SpCas9.
    Guo M; Ren K; Zhu Y; Tang Z; Wang Y; Zhang B; Huang Z
    Cell Res; 2019 Mar; 29(3):183-192. PubMed ID: 30664728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells.
    Yang Y; Li D; Wan F; Chen B; Wu G; Li F; Ren Y; Liang P; Wan J; Songyang Z
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SpRY: Engineered CRISPR/Cas9 Harnesses New Genome-Editing Power.
    Zhang D; Zhang B
    Trends Genet; 2020 Aug; 36(8):546-548. PubMed ID: 32456805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing.
    Yang ZX; Fu YW; Zhao JJ; Zhang F; Li SA; Zhao M; Wen W; Zhang L; Cheng T; Zhang JP; Zhang XB
    Genomics Proteomics Bioinformatics; 2023 Dec; 21(6):1206-1220. PubMed ID: 36549468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
    Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
    Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
    Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
    Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome Engineering in Rice Using Cas9 Variants that Recognize NG PAM Sequences.
    Hua K; Tao X; Han P; Wang R; Zhu JK
    Mol Plant; 2019 Jul; 12(7):1003-1014. PubMed ID: 30928636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the efficiency of CRISPR-Cas9-VQR precise genome editing in rice.
    Hu X; Meng X; Liu Q; Li J; Wang K
    Plant Biotechnol J; 2018 Jan; 16(1):292-297. PubMed ID: 28605576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SpCas9- and LbCas12a-Mediated DNA Editing Produce Different Gene Knockout Outcomes in Zebrafish Embryos.
    Meshalkina DA; Glushchenko AS; Kysil EV; Mizgirev IV; Frolov A
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32635161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating CRISPR/Cas9 genome-editing activity by small molecules.
    Chen S; Chen D; Liu B; Haisma HJ
    Drug Discov Today; 2022 Apr; 27(4):951-966. PubMed ID: 34823004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Updates of the CRISPR/Cas9 Genome Editing System: Novel Approaches to Regulate Its Spatiotemporal Control by Genetic and Physicochemical Strategies.
    Allemailem KS; Almatroudi A; Rahmani AH; Alrumaihi F; Alradhi AE; Alsubaiyel AM; Algahtani M; Almousa RM; Mahzari A; Sindi AAA; Dobie G; Khan AA
    Int J Nanomedicine; 2024; 19():5335-5363. PubMed ID: 38859956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing by miniature CRISPR/Cas12f1 enzyme in Escherichia coli.
    Okano K; Sato Y; Hizume T; Honda K
    J Biosci Bioeng; 2021 Aug; 132(2):120-124. PubMed ID: 34023220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New variants of CRISPR RNA-guided genome editing enzymes.
    Murovec J; Pirc Ž; Yang B
    Plant Biotechnol J; 2017 Aug; 15(8):917-926. PubMed ID: 28371222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can SpRY recognize any PAM in human cells?
    Ye J; Xi H; Chen Y; Chen Q; Lu X; Lv J; Chen Y; Gu F; Zhao J
    J Zhejiang Univ Sci B; 2022 May; 23(5):382-391. PubMed ID: 35557039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution structure and dynamics of anti-CRISPR AcrIIA4, the Cas9 inhibitor.
    Kim I; Jeong M; Ka D; Han M; Kim NK; Bae E; Suh JY
    Sci Rep; 2018 Mar; 8(1):3883. PubMed ID: 29497118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.